SIGA SIGA TECHNOLOGIES INC

CIK 0001010086 50 ready 8-Ks latest August 6, 2026, 4:06 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 0 baseline

Ready 8-Ks 50

Latest filing August 6, 2026, 4:06 PM ET

Top materiality 0.85

Event mix earnings ×20 · other_material ×11 · leadership ×11

Sentiment 19 pos · 11 neg · 20 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for SIGA

Highest-materiality recent filing

SIGA reports Q2 2025 product revenues $79.1M, net income $35.5M, EPS $0.49; new BARDA funding $27M

August 5, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Record quarterly total revenue of $195.5M, up 29.4% from $151.1M in Q2 2024, including $79.1M product sales
Net income of $35.5M ($0.49 diluted EPS) versus $1.8M ($0.03) in Q2 2024; operating income $45.7M vs $1.1M

Read filing →

August 6, 2026, 4:06 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

SIGA Q2 2026 revenue drops 49% YoY to $41M; EPS $0.17 vs $0.49

Product sales $37.9M in Q2 2026, down from $79.1M in Q2 2025; total revenues $41.0M vs $81.1M.
June 10, 2026, 4:05 PM ET other material materiality 0.40 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

SIGA shareholders approve 6.5M share increase in 2010 Stock Incentive Plan

Stockholders voted 38.8M for, 12.4M against, 20,559 abstain; broker non-votes 11.2M.
May 7, 2026, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01 ◈ Earnings Releases

SIGA Q1 net loss widens to $3.5M; revenue falls to $6.2M

Product sales $3.5M vs $5.8M YoY; total revenue $6.2M vs $7.0M.
March 26, 2026, 7:59 PM ET dividend materiality 0.65 positive item 8.01

SIGA declares special $0.60/share dividend payable April 23

Special one-time cash dividend of $0.60 per common share declared.
March 10, 2026, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

SIGA 2025 product revenue $88M, down 34% YoY; net income $23.3M vs $59.2M

Product revenues of $88M in 2025, down from $133M in 2024; total revenues $94.6M.
November 6, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

SIGA reports Q3 2025 net loss of $6.4M on $2.6M revenue, down from $1.3M income YoY

Q3 2025 product sales fell to $0.9M from $8.9M YoY; total revenue $2.6M vs $10.0M.
August 5, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

SIGA reports Q2 2025 product revenues $79.1M, net income $35.5M, EPS $0.49; new BARDA funding $27M

Record quarterly total revenue of $195.5M, up 29.4% from $151.1M in Q2 2024, including $79.1M product sales
June 12, 2025, 7:59 PM ET other material materiality 0.30 neutral item 5.03 item 5.07 item 9.01 ◈ Governance Changes

SIGA shareholders elect board, ratify auditor, approve officer liability amendment at 2025 annual meeting

All eight director nominees elected; highest vote total 52.1M for John M. Keane; lowest 47.8M for Joseph W. Marshall.
May 8, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

SIGA Q1 2025 net loss $0.4M, revenue $7.0M; special dividend $0.60

Q1 2025 total revenues $7.0M (down 72% YoY); net loss $0.4M ($0.01 EPS) vs net income $10.3M ($0.14 EPS) in Q1 2024.
April 8, 2025, 7:59 PM ET dividend materiality 0.60 positive item 8.01

SIGA declares special one-time dividend of $0.60/share payable May 15, 2025

Special one-time cash dividend of $0.60 per share declared on April 8, 2025.
March 18, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

SIGA Technologies appoints General John M. Keane to Board of Directors

Gen. Keane appointed effective March 17, 2025; term expires at next annual meeting.
March 11, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

SIGA FY2024 net income $59.2M ($0.82 EPS); product sales $133M, up 2% YoY

Product sales were $133M in 2024 vs $130.7M in 2023, including $100M to US SNS.
December 13, 2024, 6:59 PM ET other materiality 0.15 neutral item 5.03 item 9.01 ◈ Governance Changes

SIGA Technologies amends bylaws to update stockholder nomination procedures and proxy rules

Board amended and restated bylaws effective Dec 10, 2024.
December 10, 2024, 6:59 PM ET other material materiality 0.85 negative item 8.01 item 9.01

SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped

Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.
November 7, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

SIGA reports Q3 product revenues $8.9M; receives $122M in procurement orders from US government

Product revenues $8.9M (Q3 2024) vs $8.0M YoY; total revenues $10.0M.
October 4, 2024, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01

SIGA shifts CFO and CSO comp to equity-heavy mix; bonus targets cut from 100% to 50% of salary by 2026

CFO Luckshire and CSO Hruby target annual bonus drops to 75% of base salary in 2025, then 50% from 2026 onward.
September 23, 2024, 7:59 PM ET leadership materiality 0.50 negative item 5.02 ◈ executive_change ×2

SIGA Technologies terminates EVP and CMO Dr. Jay Varma effective immediately

Dr. Jay Varma terminated as EVP and Chief Medical Officer on September 23, 2024.
September 20, 2024, 7:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change ×2

SIGA Technologies CMO and Board Member Jay Varma begins indefinite leave

Dr. Jay K. Varma commenced indefinite leave as EVP, Chief Medical Officer and board member on Sept 19, 2024.
August 15, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

SIGA's tecovirimat misses primary endpoint in PALM 007 mpox trial; shows benefit in subgroups

PALM 007 did not meet primary endpoint of statistically significant improvement in time to lesion resolution.
August 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

SIGA Q2 product sales $20.7M, net income $1.8M; receives $113M U.S. order in July

Product sales $20.7M in Q2 (vs $1.3M prior year); total revenues $21.8M; net income $1.8M or $0.03 diluted EPS.
July 19, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

SIGA receives $113M US government procurement order for oral TPOXX

U.S. HHS exercised procurement option for ~$113M of oral TPOXX treatment courses under current contract.
June 13, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07

SIGA stockholders elect nine directors and ratify PwC as auditor for FY2024

90.04% of shares represented at June 11, 2024 annual meeting.
May 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend

Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.
April 1, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01 ◈ Material Agreements

SIGA assumes primary responsibility for oral TPOXX promotion; Meridian retains limited rights in EU/UK/AU/JP/CH

Amendment to Promotion Agreement effective June 1, 2024; SIGA takes over global advertising, promotion and sale of oral TPOXX.
March 12, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

SIGA Technologies reports 2023 product sales of $131M, pre-tax operating income $84M; declares $0.60 special dividend

Product sales increased 51% YoY to $130.7M (including supportive services) for the year ended Dec 31, 2023.
January 22, 2024, 6:59 PM ET leadership materiality 0.70 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

SIGA appoints Diem Nguyen as CEO effective Jan 27, 2024; Phil Gomez retires

Diem Nguyen appointed CEO and board member effective Jan 27, 2024; Phil Gomez retires Jan 26.
January 2, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

SIGA extends CEO Gomez's transition to March 31, 2024 as successor search continues

CEO Phillip Louis Gomez III will remain CEO until March 31, 2024, or earlier upon successor's start.
November 7, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

SIGA Q3 revenue $9.2M, net loss $0.4M; guides FY pre-tax income $90-100M on Q4 deliveries

Q3 2023 total revenue $9.2M, down from $72.2M YoY; net loss $0.4M vs net income $33.0M.
September 6, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

SIGA appoints Dr. Jay K. Varma as EVP and Chief Medical Officer

Dr. Varma appointed EVP and CMO, effective Sept 6, 2023; continues as board member.
August 8, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

SIGA posts Q2 2023 revenue of $5.9M, net loss $2.9M; guides FY2023 pre-tax operating income $90M-$100M

Q2 total revenues $5.9M, down from $16.7M YoY; net loss $2.9M vs net income $2.0M; diluted EPS -$0.04.
July 28, 2023, 7:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

U.S. Government exercises ~$138M procurement options for oral and IV TPOXX from SIGA

BARDA contract options exercised: ~$113M oral TPOXX (delivery in 2023) and ~$25M IV TPOXX (delivery starts 2024).
July 28, 2023, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01 ◈ executive_change

CEO Phillip Gomez to retire by Jan 1, 2024; will serve as consultant for 24 months at full base salary retainer

Phillip Gomez will continue as CEO until Jan 1, 2024 or until a successor starts; possible extension if critical to a material initiative.
June 15, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

SIGA stockholders elect eight directors, ratify auditor, approve say-on-pay and three-year frequency

All eight director nominees elected with majority support; Jaymie A. Durnan received 45.6M for, 5.7M withheld.
May 4, 2023, 7:59 PM ET dividend materiality 0.60 positive item 8.01 item 9.01

SIGA declares special $0.45/share cash dividend payable June 1, 2023

Special cash dividend of $0.45 per share declared by the Board of Directors.
May 4, 2023, 7:59 PM ET earnings materiality 0.55 negative item 2.02 item 9.01 ◈ Earnings Releases

SIGA Q1 revenues $8.3M, net loss $0.9M; declares $0.45 special dividend

Q1 2023 revenues $8.3M vs $10.5M in Q1 2022; net loss $0.9M ($0.01 diluted loss per share).
March 2, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

SIGA reports FY2022 revenue $110.8M, net income $33.9M; international sales surge to $71M

FY2022 total revenues $110.8M (down from $133.7M in 2021); net income $33.9M ($0.46 diluted EPS vs $0.91).
January 17, 2023, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change

SIGA Technologies CEO Phil Gomez plans 2023 retirement; board launches CEO search

CEO Phil Gomez announced retirement in 2023; will remain CEO until successor starts.
November 14, 2022, 6:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change ×2

SIGA Technologies appoints Harold Ford and Dr. Jay Varma to board effective Nov 10

Harold Ford and Jay Varma, MD appointed as directors effective November 10, 2022.
November 3, 2022, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

SIGA Q3 2022 revenue surges to $72.2M from $4.8M YoY; net income of $33.0M vs loss

Q3 2022 total revenues $72.2M, compared to $4.8M in Q3 2021; net income $33.0M ($0.45 diluted EPS).
August 9, 2022, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

SIGA receives BARDA $26M procurement option exercise for IV TPOXX; deliveries targeted for 2023

BARDA exercises procurement options valued at approximately $26M for IV TPOXX under contract 19C.
August 4, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 5.02 item 9.01 ◈ executive_change

SIGA Q2 revenue $16.7M (+92% YoY); special dividend; director resigns

Q2 revenue $16.7M (up 92% YoY); net income $2.0M, diluted EPS $0.03 vs ($0.00).
July 12, 2022, 7:59 PM ET other material materiality 0.72 positive item 8.01 item 9.01

SIGA announces ~$28M in international orders for oral TPOXX amid monkeypox outbreak

Orders include $26M from Canada (PHAC & DND) and $2M from two new jurisdictions (Europe, Asia Pacific).
June 16, 2022, 7:59 PM ET other materiality 0.10 neutral item 5.03 item 5.07 item 9.01

SIGA shareholders approve charter amendment removing expired bankruptcy provisions

Charter amendment approved at June 14, 2022 annual meeting removes inoperative Bankruptcy Provisions tied to 2016 Plan of Reorganization.
May 5, 2022, 7:59 PM ET dividend materiality 0.65 positive item 8.01 item 9.01

SIGA declares special cash dividend of $0.45 per share

Special dividend of $0.45 per share, payable June 2, 2022.
May 5, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

SIGA Q1 revenue doubles to $10.5M; net loss narrows; declares special $0.45 dividend

Q1 total revenues $10.5M vs $4.8M YoY; operating loss improved to $1.4M from $2.0M.
March 24, 2022, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 ◈ executive_change

SIGA Technologies general counsel and CAO Robin Abrams resigns effective April 15, 2022

Robin E. Abrams resigned as General Counsel and CAO effective April 15, 2022.
March 3, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

SIGA reports 2021 revenue $133.7M, net income $69.5M; EPS $0.91; EMA approves TPOXX

FY2021 total revenues $133.7M; net income $69.5M ($0.91 diluted EPS) vs $56.3M ($0.71) in FY2020.
December 15, 2021, 6:59 PM ET other materiality 0.10 neutral item 5.03 item 9.01

SIGA Technologies amends bylaws; removes 2016 Reorganization Plan provisions, adds majority-vote amendment requirement

Board amended and restated bylaws effective Dec. 9, 2021.
November 4, 2021, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

SIGA reports Q3 revenue drop to $4.8M, net loss of $3.1M; secures $113M BARDA order for Q4

Total revenues $4.8M in Q3 2021 vs $44.3M in Q3 2020; net loss $3.1M ($0.04 diluted loss) vs net income $24.2M ($0.31 diluted EPS).
September 15, 2021, 7:59 PM ET other material materiality 0.50 neutral item 8.01

DoD intends to negotiate sole-source contract with SIGA for TPOXX; size and timing not disclosed

DoD publicly disclosed intent to negotiate a firm fixed-price sole-source contract for TPOXX.

Executive changes

Appointed

John M. Keane

Director

SIGA · SIGA TECHNOLOGIES INC

Effective: 2025-03-17
Filed: March 18, 2025, 7:59 PM ET

the Board appointed as a director of the Company General John M. “Jack” Keane (Ret.), effective immediately

Departed

Dr. Jay Varma

Director

SIGA · SIGA TECHNOLOGIES INC

Effective: 2024-09-23
Filed: September 23, 2024, 7:59 PM ET

Pursuant to the terms of his employment agreement, Dr. Varma’s service on the Company’s Board of Directors also automatically ended effective immediately.

Departed

Dr. Jay Varma

Executive Vice President and Chief Medical Officer

SIGA · SIGA TECHNOLOGIES INC

Effective: 2024-09-23
Filed: September 23, 2024, 7:59 PM ET

On September 23, 2024, the Board of Directors of SIGA Technologies, Inc. (the “Company”) terminated Dr. Jay Varma, effective immediately, other than for cause, from his position as Executive Vice President and Chief Medical Officer of the Company.

Departed

Jay K. Varma

Executive Vice President and Chief Medical Officer

SIGA · SIGA TECHNOLOGIES INC

Effective: 2024-09-19
Filed: September 20, 2024, 7:59 PM ET

On September 19, 2024, Dr. Jay K. Varma began an indefinite leave of absence from his positions as Executive Vice President and Chief Medical Officer of SIGA Technologies, Inc. (the “Company”) and as a member of the Board of Directors of the Company.

Departed

Jay K. Varma

Member of the Board of Directors

SIGA · SIGA TECHNOLOGIES INC

Effective: 2024-09-19
Filed: September 20, 2024, 7:59 PM ET

On September 19, 2024, Dr. Jay K. Varma began an indefinite leave of absence from his positions as Executive Vice President and Chief Medical Officer of SIGA Technologies, Inc. (the “Company”) and as a member of the Board of Directors of the Company.

Appointed

Diem Nguyen

Chief Executive Officer

SIGA · SIGA TECHNOLOGIES INC

Effective: 2024-01-27
Filed: January 22, 2024, 6:59 PM ET

On January 22, 2024, SIGA Technologies, Inc. (the “Company”) announced the appointment of Diem Nguyen, Ph.D., MBA, as Chief Executive Officer of the Company and a member of the Company’s Board of Directors, in each case, effective as of January 27, 2024

Appointed

Dr. Jay K. Varma

Executive Vice President and Chief Medical Officer

SIGA · SIGA TECHNOLOGIES INC

Effective: 2023-09-06
Filed: September 6, 2023, 7:59 PM ET

On September 6, 2023, SIGA Technologies, Inc. (the “Company”) issued a press release announcing the appointment of Dr. Jay K. Varma as Executive Vice President and Chief Medical Officer of the Company.

Departed

Phillip Louis Gomez, III

Chief Executive Officer

SIGA · SIGA TECHNOLOGIES INC

Filed: July 28, 2023, 7:59 PM ET

Dr. Gomez will continue to serve as Chief Executive Officer of the Company until the earlier of (A) January 1, 2024, or (B) the date a new Chief Executive Officer commences services with the Company in such role

Departed

Phillip Gomez

Chief Executive Officer

SIGA · SIGA TECHNOLOGIES INC

Filed: January 17, 2023, 6:59 PM ET

On January 13, 2023, Phillip Gomez provided notice to SIGA Technologies, Inc. (the “Company”) of his intent to retire as Chief Executive Officer of the Company in 2023 and to resign from the Board of Directors (the “Board”) when he ceases to serve as Chief Executive Officer.

Appointed

Jay Varma

Director

SIGA · SIGA TECHNOLOGIES INC

Effective: 2022-11-10
Filed: November 14, 2022, 6:59 PM ET

the Board appointed Harold Ford and Jay Varma, MD as directors of the Company, effective immediately.

Appointed

Harold Ford

Director

SIGA · SIGA TECHNOLOGIES INC

Effective: 2022-11-10
Filed: November 14, 2022, 6:59 PM ET

the Board appointed Harold Ford and Jay Varma, MD as directors of the Company, effective immediately.

Departed

James Antal

Director

SIGA · SIGA TECHNOLOGIES INC

Effective: 2022-07-31
Filed: August 4, 2022, 7:59 PM ET

On July 31, 2022, James Antal provided notice to the Company of his resignation from the Board of Directors of the Company, effective immediately, due to personal health reasons.

Earnings & guidance

2026-Q1 EPS reported -$0.05 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

19 positive 11 negative 20 neutral

source · SIGA on sec.gov